ARTICLE | Company News
Amgen, Variagenics deal
January 8, 2001 8:00 AM UTC
VGNX will use its Variagenic Impact Program (VIP) to develop assays for an undisclosed therapeutic for AMGN. VIP uses bioinformatics software and experiments to measure haplotypes that correlate with ...